Pfizer/BioNTech, Moderna get CDC backing for Omicron updated booster shots
SilverV

NOTE: Updates with formal recommendation from the CDC director.

CDC Director Rochelle Walensky Thursday evening signed off on the the use of Omicron-subvariant adapted booster shots developed by Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA).
Her decision followed a vote earlier in the day from an expert CDC panel that recommended the use of the rejigged vaccines.

The decision by the CDC's Advisory Committee on Immunization Practices (ACIP) comes a day after the U.S. FDA amended the emergency use approvals for the two vaccines to allow their use as booster shots for protection against the Omicron BA.4 and BA.5 subvariants.
ACIP voted 13-1 to recommend the use of PFE/BNTX's updated bivalent shot as a booster dose for those aged 12 years and above.
ACIP voted 13-1 to recommend the use of MRNA's updated bivalent shot as a booster dose for those aged 18 years and older.
CDC's advisory committees issue non-binding recommendations which the U.S. FDA usually follows for a final decision.
The U.S. government is hoping to roll out the updated booster shots shortly after Labor Day, the New York Times reported last week.